Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | AGXT | P21549 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 4/20 | 0.37 |
| ▸ | NOS2 | P35228 | 4/20 | 0.37 |
| ▸ | NOS1 | P29475 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.31 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14853023 | 1.00 | MAPT (0.38) | MAPTCASP1AGXTAURKATTK | |
| SCHEMBL14853183 | 0.79 | CCR1 (0.39) | MAPTCASP1AGXTAURKATTK | |
| SCHEMBL29295060 | 0.79 | AOC3 (0.37) | MAPTAGXTNOS3NOS2NOS1 | |
| SCHEMBL20155268 | 0.79 | MAPT (0.36) | MAPTCASP1AURKATTKAURKB | |
| SCHEMBL22207075 | 0.79 | MAPT (0.36) | MAPTCASP1AURKATTKAURKB | |
| SCHEMBL23264653 | 0.79 | UHRF1 (0.38) | MAPTCASP1AGXTAURKATTK | |
| SCHEMBL22224634 | 0.79 | HTT (0.37) | MAPTCASP1AGXTAURKATTK | |
| SCHEMBL5809638 | 0.77 | NOS3 (0.46) | MAPTAGXTNOS3NOS2NOS1 | |
| SCHEMBL7845798 | 0.76 | AGXT (0.52) | MAPTAGXTHTTRECQLCCR1 | |
| Ammonia Solution, Strong SCHEMBL29016866 | 0.75 | NOS3 (0.44) | MAPTAGXTNOS3NOS2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114630822-B | Biaryl dihydroorotate acid dehydrogenase inhibitors | 詹森生物科技公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-114174278-B | Dihydroorotate dehydrogenase inhibitors | 詹森生物科技公司 | 2024-08-23 | — | — | CN | disclosed |
| EP-3956320-B1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH INC (US) | 2023-11-29 | — | — | EP | disclosed |
| EP-4100124-A1 | HETEROCYCLIC COMPOUNDS AS DIHYDROOROTATE DEHYDROGENASE INHIBITORS | Janssen Biotech, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| CN-115427109-A | Heterocyclic compounds as dihydroorotate dehydrogenase inhibitors | 詹森生物科技公司 | 2022-12-02 | — | — | CN | disclosed |
| US-11505536-B2 | Dihydroorotate dehydrogenase inhibitors | JANSSEN BIOTECH, INC. | 2022-11-22 | — | — | US | disclosed |
| EP-4051672-A1 | FLUORINATED QUINOLINE AND QUINOXALINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| EP-4041714-A1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | Janssen Biotech, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114650988-A | Fluorinated quinoline and quinoxaline derivatives as inhibitors of dihydroorotate dehydrogenase (DHODH) for the treatment of cancer, autoimmune and inflammatory diseases | 詹森生物科技公司 | 2022-06-21 | — | — | CN | disclosed |
| CN-114286813-A | Substituted urea dihydroorotate dehydrogenase inhibitors | 詹森生物科技公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-114174278-A | Dihydroorotate dehydrogenase inhibitors | 詹森生物科技公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3956320-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | Janssen Biotech, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11505536-B2 | Dihydroorotate dehydrogenase inhibitors | DHODH, DLD, DPYD | MAPT 2616/4885CASP1 3649/4885AGXT 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.